http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201803877-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96b882006e755dfc56fcabfc5fb019f6 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4525 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-107 |
| filingDate | 2017-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97c52bc7859a8b5d48083fef9cc6f872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edaa98532832c887c8e4d8dae8f4a304 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3c22fca870318604ef8eeb8daf43002 |
| publicationDate | 2018-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201803877-A |
| titleOfInvention | Β-3 adrenergic receptor modulator for treating or preventing a disease associated with β-3 adrenergic receptors |
| abstract | The present invention relates to compounds of formula ( Ia ) and pharmaceutical compositions thereof that modulate the activity of β-3 adrenergic receptors. The compounds and pharmaceutical compositions of the present invention are directed to methods that can be used to treat β-3 adrenergic receptor-mediated disorders, such as heart failure; cardiac efficacy in the event of heart failure; death, reinfarction and heart failure-related death / Or hospitalization; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (eg, kidney injury or failure, heart valve problems, heart rhythm problems, and / or liver damage) ); Heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular death after myocardial infarction; cardiovascular death in patients with left ventricular failure or left ventricular dysfunction; left ventricle Failure; Left ventricular dysfunction; Class II heart failure using the New York Heart Association (NYHA) classification system; Class III heart failure using the New York Heart Association (NYHA) classification system; Class IV heart using the New York Heart Association (NYHA) classification system Failure; LVEF ≤ 40% based on radionuclide ventricular imaging; LVEF ≤35% based on ultrasound cardiography or ventricular angiography; and related conditions. |
| priorityDate | 2016-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 985.